This is the first study to describe the role of the MALT-LPCAT3 axis in the development of osteoarthritis.Our data supports that targeting the MALT1-LPCAT3 axis using MALT1 inhibitors or LPCAT3 siRNA-liposomes may become attractive therapies for the treatment of OA. The gene discussed is LPCAT3; the disease is osteoarthritis.